BRPI9907084B8 - processo para a preparação de uma composição compreendendo cefalosporina amorfa cristalograficamente estável - Google Patents
processo para a preparação de uma composição compreendendo cefalosporina amorfa cristalograficamente estávelInfo
- Publication number
- BRPI9907084B8 BRPI9907084B8 BRPI9907084A BR9907084A BRPI9907084B8 BR PI9907084 B8 BRPI9907084 B8 BR PI9907084B8 BR PI9907084 A BRPI9907084 A BR PI9907084A BR 9907084 A BR9907084 A BR 9907084A BR PI9907084 B8 BRPI9907084 B8 BR PI9907084B8
- Authority
- BR
- Brazil
- Prior art keywords
- preparing
- product
- composition
- high molecular
- water
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229930186147 Cephalosporin Natural products 0.000 title 1
- 229940124587 cephalosporin Drugs 0.000 title 1
- 150000001780 cephalosporins Chemical class 0.000 title 1
- 239000000047 product Substances 0.000 abstract 3
- 239000000654 additive Substances 0.000 abstract 2
- 230000000996 additive effect Effects 0.000 abstract 2
- 229960002142 cefditoren pivoxil Drugs 0.000 abstract 2
- AFZFFLVORLEPPO-UVYJNCLZSA-N cefditoren pivoxil Chemical compound S([C@@H]1[C@@H](C(N1C=1C(=O)OCOC(=O)C(C)(C)C)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C AFZFFLVORLEPPO-UVYJNCLZSA-N 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000008240 homogeneous mixture Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP192098 | 1998-01-07 | ||
| PCT/JP1999/000020 WO1999034832A1 (fr) | 1998-01-07 | 1999-01-07 | Compositions de cephalosporine amorphes, stables du point de vue cristallographique et procede de preparation de ces compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR9907084A BR9907084A (pt) | 2000-10-17 |
| BRPI9907084B1 BRPI9907084B1 (pt) | 2017-04-25 |
| BRPI9907084B8 true BRPI9907084B8 (pt) | 2021-05-25 |
Family
ID=11515039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9907084A BRPI9907084B8 (pt) | 1998-01-07 | 1999-01-07 | processo para a preparação de uma composição compreendendo cefalosporina amorfa cristalograficamente estável |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6342493B1 (cs) |
| EP (1) | EP1051978B1 (cs) |
| JP (1) | JP3413406B2 (cs) |
| KR (1) | KR100435315B1 (cs) |
| CN (1) | CN1151845C (cs) |
| AU (1) | AU736555B2 (cs) |
| BR (1) | BRPI9907084B8 (cs) |
| CA (1) | CA2316841C (cs) |
| CZ (1) | CZ302082B6 (cs) |
| EA (1) | EA002881B1 (cs) |
| ES (1) | ES2393972T3 (cs) |
| HU (1) | HU230295B1 (cs) |
| ID (1) | ID25469A (cs) |
| IL (2) | IL137004A0 (cs) |
| NZ (1) | NZ505871A (cs) |
| PL (1) | PL194097B1 (cs) |
| PT (1) | PT1051978E (cs) |
| SK (1) | SK286631B6 (cs) |
| TR (1) | TR200001903T2 (cs) |
| TW (1) | TW587946B (cs) |
| UA (1) | UA70311C2 (cs) |
| WO (1) | WO1999034832A1 (cs) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK286631B6 (sk) * | 1998-01-07 | 2009-02-05 | Meiji Seika Kaisha Ltd. | Žltá prášková kompozícia na orálne podávanie a spôsob jej prípravy |
| UY26380A1 (es) | 1999-10-08 | 2001-04-30 | Smithkline Beecham Corp | Inhibidores de fab i |
| ES2320984T3 (es) | 2001-04-06 | 2009-06-01 | Affinium Pharmaceuticals, Inc. | Inhibidores de fab i. |
| AU2002253642B2 (en) * | 2001-04-26 | 2007-05-24 | Meiji Seika Kaisha, Ltd. | Amorphous cefditoren pivoxil composition and process for producing the same |
| KR101019769B1 (ko) * | 2002-10-02 | 2011-03-04 | 메이지 세이카 가부시키가이샤 | 경구 흡수성이 개선된 항균성 약제학적 조성물 |
| JP4859460B2 (ja) | 2002-12-06 | 2012-01-25 | アフィニウム ファーマシューティカルズ， インク． | ヘテロ環化合物、その製造方法および治療におけるその使用 |
| CA2519429C (en) * | 2003-03-17 | 2013-08-06 | Affinium Pharmaceuticals, Inc. | Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics |
| WO2004113451A1 (ja) * | 2003-06-20 | 2004-12-29 | Meiji Seika Kaisha, Ltd. | 難溶性物質と水溶性高分子との共沈物およびその製造方法 |
| PT1671635E (pt) * | 2003-10-08 | 2012-01-17 | Meiji Seika Pharma Co Ltd | Composição de antibiótico amorfo contendo cefditoreno pivoxil |
| EP1689755A2 (en) * | 2003-11-07 | 2006-08-16 | Ranbaxy Laboratories Limited | Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin |
| JP2005162696A (ja) * | 2003-12-04 | 2005-06-23 | Nichiko Pharmaceutical Co Ltd | 溶出性に優れたセフジトレンピボキシル製剤 |
| WO2005082330A2 (en) * | 2004-02-19 | 2005-09-09 | Ranbaxy Laboratories Limited | Co-precipitated amorphous cefditoren pivoxil and dosage forms comprising the same |
| CA2568914C (en) | 2004-06-04 | 2013-09-24 | Affinium Pharmaceuticals, Inc. | Therapeutic agents, and methods of making and using the same |
| US20080069879A1 (en) * | 2006-05-02 | 2008-03-20 | Ravishekhar Bhiwgade | Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof |
| US8318720B2 (en) | 2006-07-20 | 2012-11-27 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as Fab I inhibitors |
| WO2008057058A1 (en) * | 2006-11-10 | 2008-05-15 | Nobel Ilac Sanayii Ve Ticaret As | Oral pharmaceutical compositions |
| EP3255045A1 (en) | 2007-02-16 | 2017-12-13 | Debiopharm International SA | Salts, prodrugs and polymorphs of fab i inhibitors |
| CN101560216B (zh) * | 2009-05-27 | 2011-06-15 | 上海交通大学 | 头孢妥仑酯的制备方法 |
| EP2595631A4 (en) * | 2010-07-23 | 2013-08-28 | Lupin Ltd | PHARMACEUTICAL COMPOSITIONS OF CEFDITOREN PIVOXIL |
| PH12013500603A1 (en) | 2010-09-30 | 2015-10-23 | Toyama Chemical Co Ltd | Meglumine salt of 6-flouro-3-hydroxy-2-pyrazine carboxamide |
| CN103209966B (zh) | 2010-09-30 | 2015-06-10 | 富山化学工业株式会社 | 6-氟-3-羟基-2-吡嗪甲酰胺的钠盐 |
| JP6085026B2 (ja) | 2012-06-19 | 2017-02-22 | デビオファーム インターナショナル エスエーＤｅｂｉｏｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓａ | （ｅ）−ｎ−メチル−ｎ−（（３−メチルベンゾフラン−２−イル）メチル）−３−（７−オキソ−５，６，７，８−テトラヒドロ−１，８−ナフチリジン−３−イル）アクリルアミドのプロドラッグ誘導体 |
| MX371021B (es) * | 2013-08-29 | 2020-01-13 | Cadila Healthcare Ltd | Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables. |
| EP3244879A1 (en) | 2015-01-16 | 2017-11-22 | Ögün, Yusuf Toktamis | Cefditoren pivoxil compositions with improved stability and production methods thereof |
| EP3419628B1 (en) | 2016-02-26 | 2020-10-14 | Debiopharm International SA | Medicament for treatment of diabetic foot infections |
| CN109053768A (zh) * | 2018-08-07 | 2018-12-21 | 中国医药集团总公司四川抗菌素工业研究所 | 一种无定型头孢妥仑酯的制备方法 |
| WO2020165407A1 (en) | 2019-02-14 | 2020-08-20 | Debiopharm International S.A. | Afabicin formulation, method for making the same |
| JP7418475B2 (ja) | 2019-06-14 | 2024-01-19 | デバイオファーム インターナショナル エス．エー． | バイオフィルムが関与する細菌感染症を治療するための医薬及びその使用 |
| CN110251467A (zh) * | 2019-06-26 | 2019-09-20 | 北京济美堂医药研究有限公司 | 一种无定形态头孢妥仑匹酯组合物的制备方法 |
| CN112190539B (zh) * | 2020-11-10 | 2021-11-02 | 深圳立健药业有限公司 | 一种头孢妥仑匹酯组合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0678234B2 (ja) * | 1988-04-19 | 1994-10-05 | 明治製菓株式会社 | 経口投与用抗菌組成物 |
| JPH05306227A (ja) * | 1992-04-27 | 1993-11-19 | Lion Corp | 徐放性口腔内疾患治療剤 |
| JP2576927B2 (ja) * | 1992-05-15 | 1997-01-29 | ファイザー製薬株式会社 | 細粒核 |
| JPH06316517A (ja) * | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | 放出制御製剤 |
| JPH0717866A (ja) * | 1993-06-16 | 1995-01-20 | Meiji Seika Kaisha Ltd | 医薬組成物 |
| WO1996019239A1 (fr) | 1994-12-21 | 1996-06-27 | Yamanouchi Pharmaceutical Co., Ltd. | Composition solide a solubilite et absorbabilite ameliorees |
| AR004014A1 (es) * | 1995-10-13 | 1998-09-30 | Meiji Seika Kaisha | Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion |
| ES2212810T3 (es) | 1996-05-20 | 2004-08-01 | Janssen Pharmaceutica N.V. | Composiciones antifungicas con biodisponibilidad mejorada. |
| US6294669B1 (en) | 1996-09-20 | 2001-09-25 | Meiji Seika Kaisha Ltd. | Crystalline substance of cefditoren pivoxyl and the production of the same |
| SK286631B6 (sk) * | 1998-01-07 | 2009-02-05 | Meiji Seika Kaisha Ltd. | Žltá prášková kompozícia na orálne podávanie a spôsob jej prípravy |
-
1999
- 1999-01-07 SK SK1026-2000A patent/SK286631B6/sk not_active IP Right Cessation
- 1999-01-07 ES ES99900136T patent/ES2393972T3/es not_active Expired - Lifetime
- 1999-01-07 IL IL13700499A patent/IL137004A0/xx unknown
- 1999-01-07 PT PT99900136T patent/PT1051978E/pt unknown
- 1999-01-07 CA CA002316841A patent/CA2316841C/en not_active Expired - Lifetime
- 1999-01-07 ID IDW20001303A patent/ID25469A/id unknown
- 1999-01-07 US US09/582,937 patent/US6342493B1/en not_active Expired - Lifetime
- 1999-01-07 AU AU17845/99A patent/AU736555B2/en not_active Ceased
- 1999-01-07 BR BRPI9907084A patent/BRPI9907084B8/pt not_active IP Right Cessation
- 1999-01-07 EP EP99900136A patent/EP1051978B1/en not_active Expired - Lifetime
- 1999-01-07 KR KR10-2000-7007546A patent/KR100435315B1/ko not_active Expired - Lifetime
- 1999-01-07 TR TR2000/01903T patent/TR200001903T2/xx unknown
- 1999-01-07 HU HU0101272A patent/HU230295B1/hu unknown
- 1999-01-07 JP JP2000527279A patent/JP3413406B2/ja not_active Expired - Lifetime
- 1999-01-07 EA EA200000742A patent/EA002881B1/ru not_active IP Right Cessation
- 1999-01-07 WO PCT/JP1999/000020 patent/WO1999034832A1/ja active IP Right Grant
- 1999-01-07 CZ CZ20002542A patent/CZ302082B6/cs not_active IP Right Cessation
- 1999-01-07 NZ NZ505871A patent/NZ505871A/xx not_active IP Right Cessation
- 1999-01-07 PL PL99341589A patent/PL194097B1/pl unknown
- 1999-01-07 CN CNB998027855A patent/CN1151845C/zh not_active Expired - Lifetime
- 1999-06-28 TW TW088110903A patent/TW587946B/zh not_active IP Right Cessation
- 1999-07-01 UA UA2000084638A patent/UA70311C2/uk unknown
-
2000
- 2000-06-26 IL IL137004A patent/IL137004A/en not_active IP Right Cessation
-
2001
- 2001-11-26 US US09/991,694 patent/US6486149B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI9907084B8 (pt) | processo para a preparação de uma composição compreendendo cefalosporina amorfa cristalograficamente estável | |
| HUT67653A (en) | Nor-bile-acid derivatives, process for producing them and pharmaceutical compositions containing them | |
| CA2334773A1 (en) | Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use | |
| BR0007781A (pt) | Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf | |
| LTIP862A (en) | Method for preparing amino acid derivatives and pharmaceuthical compositions thereof | |
| PT81264B (pt) | Processo para a preparacao de solucoes injectaveis estabilizadas de piroxicamo | |
| AP9801378A0 (en) | 9-amino-3- keto erythromycin derivatives. | |
| GB8727483D0 (en) | Derivatives of cyclohexane | |
| IL102814A0 (en) | Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them | |
| EP0992509A3 (en) | Novel macrolide derivatives | |
| EP0233946A4 (en) | CHROMOGLYCIC ACID DERIVATIVES, PREPARATION METHOD AND MEDICINAL COMPOSITION. | |
| GR3026209T3 (en) | Compositions containing quinolone antibiotics and sulfonate of polystyrol. | |
| EP0537492A3 (en) | Stable salts of 5,10-methylenetetrahydrofolic acid | |
| AP9801377A0 (en) | Tricyclic erythromycin derivatives. | |
| DE3369983D1 (en) | Isoquinoline derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| IE40957B1 (en) | A 4-0- ,d glucopyransyl-2-deoxystreptamine, a process for its preparing, and compositions incorporating it | |
| AU569013B2 (en) | 2-phenoxymethyl-imidazoline derivatives | |
| ES2100177T3 (es) | Compuestos de cefalosporina y su produccion. | |
| IL148739A0 (en) | 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use | |
| IL108997A0 (en) | Heterotricyclically substituted phenyl-cyclohexane-carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them | |
| IL66473A0 (en) | Aminoglycoside derivatives,their production and pharmaceutical compositions containing them | |
| IE56229B1 (en) | 2-piperazinyl-or-homopiperazinyl-quinazoline derivatives their production and pharmaceutical compositions containing them | |
| IE38961B1 (en) | Benzylamine derivatives | |
| CA2119661A1 (fr) | Nouveaux composes de n-benzylpiperazine, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
| SE8204792L (sv) | N-metyl-d-glukaminsalt av 3,4-dihydro-5-metyl-6-(2-metyl-propyl)-4-oxotieno(2,3-d)pyrimidin-2-karboxylsyra och farmaceutisk komposition innehallande detta salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT.CL: A61K 9/14, A61K 31/545, A61K 31/546, C07D 501/00, C07D 501/24 Ipc: A61K 47/38 (2009.01), C07D 501/24 (2009.01) |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O,13 E 25 DA LPI. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09Y | Publication of grant cancelled [chapter 9.1.2 patent gazette] |
Free format text: REFERENCIA RPI 2147- CODIGO 9.1 |
|
| B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: MEIJI SEIKA KAISHA, LTD (JP) Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 20120104493/RJ, DE 08/11/2012, E NECESSARIO APRESENTAR O DOCUMENTO DE ALTERACAO DE NOME NOTARIZADO E COM A DEVIDA LEGALIZACAO CONSULAR. |
|
| B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: MEIJI SEIKA KAISHA, LTD (JP) Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 20130077706/RJ DE 23/09/2013, E NECESSARIO APRESENTAR O DOCUMENTO DE ALTERACAO NOTARIZADO E COM A DEVIDA LEGALIZACAO CONSULAR. |
|
| B25E | Requested change of name of applicant rejected |
Owner name: MEIJI SEIKA KAISHA, LTD (JP) Free format text: INDEFERIDO(S) O(S) PEDIDO(S) DE ALTERACAO(OES) DE NOME CONTIDO(S) NA PETICAO NO 20120104493, DE 08/11/2012, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2291, DE 02/12/2014. |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
| B25D | Requested change of name of applicant approved | ||
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/01/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 07/01/2019 |